Promising new Cervical Cancer Treatment
By Lindsay Braun, Ivanhoe Health Correspondent
TAMPA, Fla. (Ivanhoe Newswire) -- Cervical cancer is the most common type of gynecologic cancer, caused most commonly by human papillomavirus (HPV). A new, effective treatment for cervical cancer may be on the horizon and is showing positive outcomes in clinical trials.
Brad Monk, M.D., researcher at the University of California, Irvine, presented his findings of a phase II clinical trial of an injectable drug called bevacizumab (Avastin) for the treatment of recurrent cervical cancer at the annual meeting of the Society of Gynecologic Oncologists in Tampa, Fla.
Bevacizumab works by attacking vascular endothelial growth factor (VEGF), a key promoter of tumor progression. It has been FDA approved to treat breast cancer, colorectal cancer and lung cancer. “Bevacizumab is the most developed approach to fight VEGF,” Dr. Monk told Ivanhoe.
During the phase II study of bevacizumab as a treatment for cervical cancer, Dr. Monk and his team studied 46 patients with recurrent cervical cancer who had received prior unsuccessful treatments. After six months of study, 24 percent of the patients involved in study had experienced no cancer progression.
“It appears to be well tolerated in heavily pretreated women with recurrent cervical cancer,” Dr. Monk said. “Our next step is to determine which patients are best suited for this type of therapy.”
Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.
SOURCE: Ivanhoe interview with Brad Monk, M.D., Annual meeting of the Society of Gynecologic Oncologists in Tampa, Fla., March 9-12, 2008.